DWTX

In the past six months, Dogwood Therapeutics' stock price has been impacted by several events, including the enrollment of patients in its Halneuron® Phase 2b trial, positive interim Phase 2b clinical trial results for Halneuron®, financing to progress Halneuron® through Phase 2b development, and securing a global license for SP16 IV. The FDA accepted Dogwood Therapeutics' Investigational New Drug (IND) application for SP16 IV and Dogwood Therapeutics announced a worldwide development and commercialization partnership with PRIDCor Therapeutics, LLC for its antiviral assets IMC-1 and IMC-2. The stock has experienced significant volatility, with a 52-week range of $1.28 to $9.50.